Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC 4 E trial in 15 European countries.
Xiao LiJoke BilckeAlike W van der VeldenRobin BruyndonckxSamuel CoenenEmily BongardMuirrean de PaorSlawomir ChlabiczMaciek Godycki-CwirkoNick A FrancisRune Munck AabenhusHeiner C BucherAnnelies ColliersAn De SutterAna García-SangenísDominik GlinzNicolay Jonassen HarbinKatarzyna KosiekMorten LindbækChristos LionisCarl LlorRéka Mikó-PauerRuta Radzeviciene JurguteBohumil SeifertPär-Daniel SundvallPia Touboul LundgrenNikolaos TsakountakisTheo J VerheijHerman GoossensChristopher C ButlerPhilippe Beutelsnull nullPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2022)
Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers' perspective (if willingness-to-pay per QALY gained > €22,459) and cost-saving in adults/adolescents from a societal perspective.